Functional characterization of 2q22.1 deletion in oral squamous cell carcinoma

口腔鳞状细胞癌2q22.1缺失的功能特征

基本信息

  • 批准号:
    10285990
  • 负责人:
  • 金额:
    $ 5.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-02 至 2024-09-01
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Oral squamous cell carcinoma (OSCC) affects approximately 350,000 patients worldwide. The primary causes of OSCC include smoking, consumption of alcoholic beverages, and infections with high-risk human papillomaviruses (HPV). Currently, the main therapeutic modalities offered to patients include surgery, radiation, chemotherapy, and immunotherapy. Despite the existing clinical interventions, the mortality for this disease remains approximately 20% and is greater for higher grade tumors. OSCC tumors are genetically heterogenous with a high rate of point mutations and somatic copy number variations (CNVs). Similar CNV patterns are commonly observed in other squamous cell carcinomas such as those arising from the lung, cervix, and esophagus. The CNVs also have a high propensity for co-occurring with inactivating mutations of tumor suppressor genes. However, despite discoveries documenting the presence of various genomic loci undergoing copy number alterations, the mechanistic contributions of these CNVs to OSCC carcinogenesis have yet to be determined. The early and most frequent genetic alterations in OSCC include loss of tumor suppressors CDKN2A (residing at 9p) in conjunction with mutations in TP53 (residing at 17p). Additionally, one of the most commonly deleted sites within OSCC tumors is located at 2q22.1. This deletion is entirely contained within the low-density lipoprotein receptor-related protein 1B gene, LRP1B, which has been implicated as a tumor suppressor in other cancers but has not been characterized in OSCC. Although deletions at this locus occur more frequently than would be expected by chance, inactivating point mutations within this gene are not common. Moreover, LRP1B is not expressed in oral keratinocytes, raising the question as to why the deletions at this locus occur at such a high frequency, despite the lack of gene expression. This suggests these deletions act by a mechanism that is independent of interfering with LRP1B function. Therefore, I hypothesize that chromosomal deletions at 2q22.1 act as driver events in OSCC progression via alteration of intragenic elements that function in tumor suppression. This proposal will address my hypothesis via three specific aims: 1) Determine the impact of 2q22.1 chromosomal deletions on the tumorigenic behavior of keratinocytes in vitro, 2) Identify mechanisms downstream of 2q22.1 deletion responsible for tumorigenic behavior, and 3) Identify the minimal critical region responsible for the observed phenotypic changes. These aims will be achieved utilizing a combination of biochemical and molecular biology techniques to create the deletions observed in patient samples in wild type keratinocytes and assess their contribution to tumorigenic behavior. Outcomes from this investigation will be used in the development of novel therapeutic applications for suppression of OSCC and potentially various other cancers that originate from the squamous epithelium.
项目摘要/摘要 口腔鳞状细胞癌(OSCC)影响全世界约35万患者。主要原因 口腔鳞状细胞癌包括吸烟、饮酒和感染高危人群。 乳头瘤病毒(HPV)。目前,提供给患者的主要治疗方式包括手术,放射, 化疗和免疫疗法。尽管现有的临床干预措施,这种疾病的死亡率 保持约20%,并且对于更高级别的肿瘤更高。口腔鳞状细胞癌肿瘤是遗传异质性的 具有高的点突变率和体细胞拷贝数变异(CNVs)。类似的CNV模式是 通常在其他鳞状细胞癌中观察到,例如来自肺、子宫颈的鳞状细胞癌, 食道CNV还具有与肿瘤细胞的失活突变共同发生的高倾向性。 抑制基因然而,尽管发现记录了各种基因组位点的存在, 拷贝数的改变,这些CNV对OSCC致癌作用的机制还有待进一步研究。 测定口腔鳞状细胞癌早期和最常见的遗传改变包括肿瘤抑制基因的丢失 CDKN 2A(位于9 p)与TP 53(位于17 p)中的突变结合。此外,最 OSCC肿瘤中常见的缺失位点位于2q22.1。删除的内容完全包含在 低密度脂蛋白受体相关蛋白1B基因,LRP 1B,与肿瘤有关 在其他癌症中是抑制因子,但在OSCC中尚未表征。虽然在这个位点发生缺失, 这种基因内的失活点突变并不常见,其发生率比预期的偶然性要高。 此外,LRP 1B在口腔角质形成细胞中不表达,这就提出了一个问题,即为什么在该位点的缺失 以如此高的频率发生,尽管缺乏基因表达。这表明这些缺失是通过 该机制与干扰LRP 1B功能无关。因此,我假设染色体 2q22.1的缺失通过改变基因内元件, 在肿瘤抑制中的作用。这个建议将通过三个具体目标来解决我的假设:1)确定 2q22.1染色体缺失对体外角质形成细胞致瘤行为的影响,2)鉴定 负责肿瘤发生行为的2q22.1缺失下游机制,和3)确定最小的 负责观察到的表型变化的关键区域。这些目标将利用 生物化学和分子生物学技术的组合,以产生在患者样品中观察到的缺失 在野生型角质形成细胞中,并评估它们对肿瘤发生行为的贡献。调查结果 将用于开发抑制OSCC的新型治疗应用, 源自鳞状上皮的其他癌症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ramin Farhad其他文献

Ramin Farhad的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ramin Farhad', 18)}}的其他基金

Functional characterization of 2q22.1 deletion in oral squamous cell carcinoma
口腔鳞状细胞癌2q22.1缺失的功能特征
  • 批准号:
    10669010
  • 财政年份:
    2020
  • 资助金额:
    $ 5.18万
  • 项目类别:
Functional characterization of 2q22.1 deletion in oral squamous cell carcinoma
口腔鳞状细胞癌2q22.1缺失的功能特征
  • 批准号:
    10450053
  • 财政年份:
    2020
  • 资助金额:
    $ 5.18万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.18万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了